Allergy Therapeutics Market - By Treatment (Anti-allergy drug [Antihistamine, Corticosteroid, Decongestant], Immunotherapy [SCIT, SLIT]), Type (Rhinitis, Asthma, Skin, Food, Eye), Route of Administration, Distribution Channel, Global Forecast, 2023 - 2032

Allergy Therapeutics Market - By Treatment (Anti-allergy drug [Antihistamine, Corticosteroid, Decongestant], Immunotherapy [SCIT, SLIT]), Type (Rhinitis, Asthma, Skin, Food, Eye), Route of Administration, Distribution Channel, Global Forecast, 2023 - 2032

The global allergy therapeutics market will showcase a 6.6% CAGR from 2023 to 2032. The increasing prevalence of allergies, including respiratory allergies like hay fever and food allergies, drives demand for effective treatments. Advancements in allergy diagnostics and immunotherapy techniques have improved treatment outcomes, driving business growth.

A growing awareness of allergies and their impact on health prompts individuals to seek medical intervention will bode well for the market expansion. Moreover, environmental factors like pollution and changing climate patterns lead to a higher incidence of allergies, opening a new scope for business growth.

Additionally, supportive healthcare policies, collaborative initiatives and the development of novel allergy therapeutics will further drive the market progress. Sanofi SA announced in July 2023 that it had agreed to acquire Qunol, a prominent U.S.-based brand specializing in the health and wellness industry.

The market is segregated based on treatment type, type, route of administration, distribution channel, and region.

Based on treatment type, the immunotherapy treatment segment will exhibit a 7% CAGR through 2032, driven by the increasing recognition of immunotherapy’s effectiveness in addressing the root causes of allergies, reducing symptom severity, and providing long-term relief to patients, thus driving business growth for this treatment modality.

Based on type, the asthma segment will record 7.2% CAGR during 2023-2032, driven by factors such as increasing prevalence of asthma, expanding research in asthma therapeutics, and the development of advanced and more targeted treatments for asthma patients, fueling growth in the segment.

The intranasal route of administration segment will depict a 6.8% CAGR throughout the analysis period. The convenience and patient preference for non-invasive treatments, the effectiveness of intranasal delivery in managing allergic symptoms, and continuous innovation in intranasal allergy therapies will drive growth in the segment.

Regionally, the Asia Pacific allergy therapeutics industry is estimated to grow at a 7% CAGR during the analysis timeline, driven by the region's increasing prevalence of allergies and rising healthcare infrastructure. Moreover, the expanding patient awareness and growing demand for effective allergy treatments will foster business growth in the region.